Clinical Trials in China / NCT06680362
Active, not recruiting
Observational
The Influence of Splenic Artery Characteristics in Gastric Cancer Surgery
NCT06680362 · tracked via the Priya Life Science China tracker
Condition(s) studied
GastrectomyGastric Carcinoma
Study summary
The northwest Chinese population has unique anatomical characteristics of splenic artery due to ethnic differences, which has an important impact on the development and prognosis of laparoscopic radical total gastrectomy.
Eligibility
Inclusion Criteria:
* ① The native place is in Shaanxi Province, Gansu Province, Qinghai Province, Ningxia Hui Autonomous Region, Xinjiang Uygur Autonomous Region;
* The criteria for patients undergoing laparoscopic radical total gastrectomy include: primary adenocarcinoma of the stomach in the upper third or middle third confirmed by histology; Patients with preoperative diagnosis of clinical T2-T4a (cT2-T4a) gastric cancer were free of tumor invasion of neighboring organs (pancreas, spleen, liver, and transverse colon), paraaortic or splenic hilar lymph node enlargement or fusion, and distant metastases as shown by preoperative abdominal computed tomography (CT), abdominal ultrasound, and endoscopic ultrasound; According to the postoperative pathological diagnosis, total gastrectomy, D2 lymph node resection and radical R0 resection were performed.
Exclusion Criteria:
* ① Patients who did not fully expose the anatomic characteristics of splenic hilar vessels or had evidence of peritoneal spread or distant metastasis during laparoscopic radical gastrectomy;
* Patients with incomplete clinical data;
Primary outcome measure(s)
- Disease-free survival — 1,3,5 years
Disease-free survival
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| The First Affiliated Hospital of PLA Air Force Medical University | Xi'an | Shaanxi |
More xiaohua li trials in China
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06680362 on ClinicalTrials.gov ↗ ← All trials in China